Abionic SA is a Swiss medical technology company dedicated to revolutionizing in vitro diagnostics. Founded in 2010 and based at the Biopôle innovation campus in Lausanne, Abionic develops and manufactures the abioSCOPE®, a unique nanotechnology-based rapid diagnostic platform. This platform delivers lab-quality results directly at the point of care within minutes, using a single drop of blood. Abionic's solutions aim to improve patient outcomes by enabling faster and more accurate diagnoses for critical conditions, including sepsis, allergies, and iron deficiencies. The company is committed to making cutting-edge diagnostic tools accessible to healthcare professionals worldwide, enhancing decision-making and personalizing patient care.
The headquarters serves as the central hub for Abionic's global operations, including research and development, manufacturing of its nanofluidic biosensors and the abioSCOPE® platform, as well as corporate, administrative, and strategic functions.
Features state-of-the-art laboratories, cleanroom facilities for device and test manufacturing, and modern office spaces within the dynamic Biopôle life sciences park, which fosters collaboration and innovation.
Abionic fosters a dynamic, innovative, and collaborative work environment. The culture emphasizes scientific excellence, agility, interdisciplinary teamwork, and a shared commitment to making a tangible impact on global healthcare and patient well-being.
The headquarters' location within Biopôle provides Abionic with access to a rich ecosystem of life science companies, research institutions, and talent. It's central to their ability to control the entire product lifecycle, from R&D to production, ensuring high quality and rapid innovation in point-of-care diagnostics.
Abionic's operations are primarily centralized at its headquarters in Epalinges, Switzerland. However, the company achieves a global reach for its abioSCOPE® platform and diagnostic tests through a growing network of distribution partners and strategic collaborations across Europe, Asia, the Middle East, and the Americas. They are actively expanding their market presence to make their point-of-care solutions accessible worldwide.
Biopôle, Bâtiment Alanine, Route de la Corniche 3
Epalinges (Lausanne)
Vaud
Switzerland
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Abionic' leadership includes:
Abionic has been backed by several prominent investors over the years, including:
No major C-level executive hires or departures, beyond the existing team structure, have been publicly announced by Abionic in the immediate last 12 months. The company appointed Dr. Hélène Peyro Saint-Paul as Chief Medical Officer in March 2023, strengthening its leadership team.
Discover the tools Abionic uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Abionic commonly uses the email format combining the first initial and last name, or first name and last name separated by a dot.
[first_initial][last]@abionic.com or [first].[last]@abionic.com
Format
ndurand@abionic.com or nicolas.durand@abionic.com
Example
90%
Success rate
Abionic Newsroom • May 9, 2024
Abionic announced the successful first closing of its Series C extension financing round, securing CHF 5 million. The funds will support the company's commercial expansion and continued development of its rapid diagnostic platform....more
Abionic Newsroom / Startupticker.ch • November 2, 2023
Abionic received CE Mark (IVDR) for its PSP Test, a novel sepsis diagnostic test on the abioSCOPE® platform. This allows for rapid quantitative measurement of Pancreatic Stone Protein (PSP) at the point of care, aiding in the early detection and management of sepsis....more
Abionic Newsroom • June 19, 2023
Abionic partnered with Dianosic, a French MedTech company, to improve the diagnosis pathway for patients with respiratory allergies by combining Abionic’s IVD tests with Dianosic’s CAVI-T technology for targeted corticosteroid delivery....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Abionic, are just a search away.